Surgery for early lung adenocarcinoma with specific CT findings
Part of Cancer, Lungs & breathing clinical trials.
This study looks at whether people with a very early type of lung cancer can safely have curative surgery when their CT scan shows a ground-glass type spot with certain size and shape measurements. It aims to help doctors choose the right surgery approach based on the scan features and final pathology.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early lung adenocarcinoma that is clinical stage T1N0M0, and the plan is curative (cancer-removing) surgery
- Your CT scan shows exactly one lesion (one spot) described as a ground-glass nodule, with a C/T ratio of 0.5 or less
- Your age is between 18 and 75, inclusive
- You must be willing to sign the informed consent form
- After surgery, the pathology (lab tissue test) must confirm invasive lung adenocarcinoma only (not a different cancer type)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a lung surgery approach (segmentectomy) for people with early, invasive lung cancer that shows “ground-glass” on scans. It aims to see if this less extensive surgery can treat the cancer effectively when the tumor is in a specific size and scan pattern range.
This trial is testing a lung-sparing surgery called segmentectomy for people with a certain type of lung cancer nodule. It aims to see if this surgery is a good option for those with solid-dominant nodules that are 2 to 3 cm in size and have not spread to lymph nodes.
This study compares a less invasive surgery (wedge resection) for early-stage lung cancer that appears as a ground-glass nodule on CT scans. The goal is to see if this approach works as well as standard surgery while preserving more healthy lung tissue.
This study compares two types of lung cancer surgery — removing only the part of the lung with the tumor (segmentectomy) versus removing the entire lobe (lobectomy) — for patients with early-stage lung cancer that is 2-3 cm. The goal is to see if the smaller surgery works just as well while preserving more lung function.
This trial compares removing fewer lymph nodes during surgery for early-stage non-small cell lung cancer. It is for people with a small tumor (2 cm or less) that has both solid and ground-glass parts.
This trial tests whether a more focused lymph node removal during surgery is safe and effective for people with a small, early-stage lung cancer (non-small cell type) located in the top part of the lung (apical segment).
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.